Valery Novokhatny

USPTO Granted Patents = 12 (Patent Applications = 3)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 2.2

ph-index = 5

Forward Citations = 77(Granted Patents)

Company Filing History:

7 out of 26

Grifols Therapeutics Inc.

patents

3 out of 6

Talecris Biotherapeutics, Inc.

Years Active: 2002-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9879246 - Reversibly inactivated acidified plasmin composition (2018-01-30),

2. 9028465 - Therapeutic delivery devices, systems, and methods (2015-05-12),

3. 8512980 - Recombinantly modified plasmin (2013-08-20),

4. 8420079 - Recombinantly modified plasmin (2013-04-16),

5. 8231869 - Recombinant plasmin for opthalmic indications (2012-07-31),

6. 8182808 - Recombinantly modified plasmin (2012-05-22),

7. 8101394 - Recombinantly modified plasmin (2012-01-24),

8. 8034913 - Recombinantly modified plasmin (2011-10-11),

9. 7871608 - Reversibly inactivated acidified plasmin (2011-01-18),

10. 7544500 - Process for the production of a reversibly inactive acidified plasmin composition (2009-06-09),

11. 6964764 - Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin (2005-11-15),

12. 6355243 - Method of thrombolysis by local delivery of active plasmin (2002-03-12),

Title: Valery Novokhatny: Innovator in Therapeutic Delivery Systems

Introduction

Valery Novokhatny is a prominent inventor based in Raleigh, NC (US), known for his significant contributions to the field of therapeutic delivery systems. With a total of 12 patents, he has made remarkable advancements in the development of fibrinolytic compositions and devices for delivering therapeutics.

Latest Patents

One of his latest patents is titled "Reversibly inactivated acidified plasmin composition." This invention provides a fibrinolytic composition that is useful as a therapeutic for patients experiencing thrombotic occlusions. The composition includes a reversibly inactivated acidified serine protease that is substantially free of a plasminogen activator, along with a low buffering capacity buffer and, optionally, a stabilizing agent. Another notable patent focuses on "Therapeutic delivery devices, systems, and methods." This patent outlines devices and systems designed for the delivery of therapeutics, particularly thrombolytic agents like plasmin. These innovations also address the occlusion of vessels or grafts both distal and proximal to treatment zones, as well as methods for trapping emboli.

Career Highlights

Throughout his career, Valery has worked with notable companies such as Grifols Therapeutics Inc. and Talecris Biotherapeutics, Inc. His work in these organizations has contributed to the advancement of therapeutic technologies and has positioned him as a leader in his field.

Collaborations

Valery has collaborated with several professionals, including Thomas P. Zimmerman and Jennifer Audrey Hunt, who have contributed to his innovative projects and research endeavors.

Conclusion

Valery Novokhatny's work in therapeutic delivery systems and fibrinolytic compositions showcases his dedication to improving patient care through innovation. His numerous patents reflect his expertise and commitment to advancing medical technology.

This text is generated by artificial intelligence and may not be accurate.